Blood

Cord Blood Banking Services Market to Grow at CAGR of 10.9% from 2019 to 2027: TMR Study

Stem cells, Blood, Branches of biology, Biology, Childbirth, Cord blood bank, Sibling, Cord blood, Bank, Draft:CBC Health, Relicord
Tuesday, August 11, 2020 - 4:30pm

As per Transparency Market Research, "While North America will account for a notable share of the global cord blood banking services market, Asia Pacific region will grow at a significant pace over the forecast period."

Key Points: 
  • As per Transparency Market Research, "While North America will account for a notable share of the global cord blood banking services market, Asia Pacific region will grow at a significant pace over the forecast period."
  • Key Findings of Global Cord Blood Banking Services Market Study:
    For a detailed analysis of global cord blood banking services market by type, and region, visit TOC at https://www.transparencymarketresearch.com/report-toc/1741
    Key Drivers of Growth in Global Cord Blood Banking Services Market:
    A string of notable growth factors is pushing the global cord blood banking services market, as per Transparency Market Research.
  • Request a sample of the study https://www.transparencymarketresearch.com/sample.php
    Regional Analysis of Global Cord Blood Banking Services Market:
    Major growth factors in the region would be technological advancement and its high adoption, high healthcare spending
    Competitive Landscape of Global Cord Blood Banking Services Market:
    In the global cord blood banking services market, the vendor landscape is quite fragmented.
  • Global Cord Blood Bank Services Market, by Type
    Global Cord Blood Bank Services Market, by Region

Cord Blood Banking Services Market to Grow at CAGR of 10.9% from 2019 to 2027: TMR Study

Stem cells, Blood, Branches of biology, Biology, Childbirth, Cord blood bank, Sibling, Cord blood, Bank, Draft:CBC Health, Relicord
Tuesday, August 11, 2020 - 4:30pm

As per Transparency Market Research, "While North America will account for a notable share of the global cord blood banking services market, Asia Pacific region will grow at a significant pace over the forecast period."

Key Points: 
  • As per Transparency Market Research, "While North America will account for a notable share of the global cord blood banking services market, Asia Pacific region will grow at a significant pace over the forecast period."
  • Key Findings of Global Cord Blood Banking Services Market Study:
    For a detailed analysis of global cord blood banking services market by type, and region, visit TOC at https://www.transparencymarketresearch.com/report-toc/1741
    Key Drivers of Growth in Global Cord Blood Banking Services Market:
    A string of notable growth factors is pushing the global cord blood banking services market, as per Transparency Market Research.
  • Request a sample of the study https://www.transparencymarketresearch.com/sample.php
    Regional Analysis of Global Cord Blood Banking Services Market:
    Major growth factors in the region would be technological advancement and its high adoption, high healthcare spending
    Competitive Landscape of Global Cord Blood Banking Services Market:
    In the global cord blood banking services market, the vendor landscape is quite fragmented.
  • Global Cord Blood Bank Services Market, by Type
    Global Cord Blood Bank Services Market, by Region

Wyatt Law Firm, Carabin Shaw Partner To Help COVID-19 Patients

Clinical medicine, Medicine, Medical specialties, Transfusion medicine, Blood products, Blood, Hematology, Coronavirus disease, Zoonoses, Plasmapheresis, Blood plasma
Monday, August 10, 2020 - 10:29pm

SAN ANTONIO, Aug. 10, 2020 /PRNewswire/ --San Antonio-area law firms Wyatt Law Firm, PLLC, and Carabin Shaw are partnering to assist the South Texas Blood & Tissue Center's (STBTC) efforts to collect convalescent plasma for COVID-19 patients.

Key Points: 
  • SAN ANTONIO, Aug. 10, 2020 /PRNewswire/ --San Antonio-area law firms Wyatt Law Firm, PLLC, and Carabin Shaw are partnering to assist the South Texas Blood & Tissue Center's (STBTC) efforts to collect convalescent plasma for COVID-19 patients.
  • The plasma is used to treat patients with active infections, and it is one of the few treatments available for COVID-19.
  • "The fight isn't over, so we need to continue to collect plasma from recovered COVID-19 patients," said Paula Wyatt, Founding Partner of Wyatt Law Firm.
  • "We felt it was vital for us to encourage people to make a lifesaving plasma donation," said Jamie Shaw, a partner at Carabin Shaw.

National Hemophilia Foundation and Takeda Partner with Alex Borstein to Raise Awareness of von Willebrand Disease

Entertainment, Health, Celebrity, Genetics, Managed care, General Health, Pharmaceutical, Blood, Clinical medicine, Medical specialties, Von Willebrand disease, Haemophilia, Erik Adolf von Willebrand, Coagulopathy, Bleeding, Willebrand
Monday, August 10, 2020 - 3:00pm

Her brother and uncle live with hemophilia A, her daughter has mild hemophilia, and Alex herself is a carrier of the disease.

Key Points: 
  • Her brother and uncle live with hemophilia A, her daughter has mild hemophilia, and Alex herself is a carrier of the disease.
  • "Taking an active role in the bleeding disorder community isn't a choice for me; it's a responsibility," said Borstein.
  • "Von Willebrand disease affects millions of Americans but is often overlooked, even by some healthcare professionals.
  • Takeda is proud to partner with NHF to help raise awareness around VWD.

Cerus INTERCEPT Blood System Kit Shipments Surpass 7.5 Million Treatable Platelet and Plasma Doses Since Launch

Health, Hospitals, Surgery, Pharmaceutical, Cardiology, Biotechnology, Branches of biology, Transfusion medicine, Blood products, Hematology, Coagulation system, In science, Platelet, Transfusion, Blood
Friday, August 7, 2020 - 1:30pm

Cerus Corporation (Nasdaq:CERS) announced today that INTERCEPT Blood Systems disposable kit shipments have surpassed 7.5 million treatable platelet and plasma doses globally since commercial launch.

Key Points: 
  • Cerus Corporation (Nasdaq:CERS) announced today that INTERCEPT Blood Systems disposable kit shipments have surpassed 7.5 million treatable platelet and plasma doses globally since commercial launch.
  • We have a solid track record with the safety and efficacy of our INTERCEPT products, which now surpasses more than 7.5 million treatable doses.
  • The INTERCEPT Blood System for platelets and plasma provides a proactive approach to reduce the risk of transfusion-transmitted infectious disease (TTID).
  • INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

BioLife Plasma Services Announces Opening of First Plasma Collection Center in Louisiana

Health, Infectious diseases, Hospitals, Other Health, General Health, Pharmaceutical, Biotechnology, Life sciences, Anatomy, Body fluids, Transfusion medicine, Hematology, Blood products, Blood, Blood plasma, Biopharmaceutical
Thursday, August 6, 2020 - 5:01pm

BioLife Plasma Services, part of the global biopharmaceutical company Takeda Pharmaceutical Company Limited, today announced the opening of a new plasma collection center in Baton Rouge to collect standard plasma from healthy donors.

Key Points: 
  • BioLife Plasma Services, part of the global biopharmaceutical company Takeda Pharmaceutical Company Limited, today announced the opening of a new plasma collection center in Baton Rouge to collect standard plasma from healthy donors.
  • Plasma is a lifeline for thousands of people with rare, chronic and complex diseases, and we are excited to open the first BioLife plasma collection center in Louisiana.
  • To learn more about BioLife Plasma Services, the donation process, and to schedule an appointment, please visit the BioLife website.
  • BioLife Plasma Services is an industry leader in the collection of high-quality plasma that is processed into life-saving plasma-based therapies.

DAXOR ANNOUNCES COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT WITH THE UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES

Medical specialties, Branches of biology, Medicine, Blood volume, Blood, Medical test, Major trauma
Tuesday, August 4, 2020 - 1:00pm

The partnership includes researching the effectiveness of Daxors BVA-100 diagnostic test on quantifying circulatory blood volume in the context of traumatic injury.

Key Points: 
  • The partnership includes researching the effectiveness of Daxors BVA-100 diagnostic test on quantifying circulatory blood volume in the context of traumatic injury.
  • Extensive peer-reviewed medical literature has validated Daxors BVA's enhancement of interventions through reliable and accurate blood volume measurement.
  • Daxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement.
  • Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Haemonetics First Quarter Fiscal 2021 Earnings Release Available on Investor Relations Website

Anatomy, Body fluids, Transfusion medicine, Branches of biology, Haemonetics, Blood, Hae, Conference call, Blood plasma, Toll-free telephone number
Tuesday, August 4, 2020 - 11:00am

The Company will host a conference call with investors and analysts to discuss and answer questions about the results at 8 a.m. EDT August 4, 2020.

Key Points: 
  • The Company will host a conference call with investors and analysts to discuss and answer questions about the results at 8 a.m. EDT August 4, 2020.
  • The call can be accessed with the following information:
    U.S. / Canada toll free (877) 848-8880; International (716) 335-9512
    Conference ID required for access: 3897757
    A live webcast of the call can be accessed on Haemonetics' Investor Relations website.
  • Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services.
  • To learn more about Haemonetics, visit our website at http://www.haemonetics.com .

Georgia Oncology and Hematology Consultants Opens in Brunswick, Georgia and Joins the American Oncology Network, LLC

Blood, Hematology
Monday, August 3, 2020 - 4:12pm

Fort Myers, Fla., Aug. 03, 2020 (GLOBE NEWSWIRE) -- American Oncology Network, LLC (AON) is pleased to announce the opening of Georgia Oncology and Hematology Consultants.

Key Points: 
  • Fort Myers, Fla., Aug. 03, 2020 (GLOBE NEWSWIRE) -- American Oncology Network, LLC (AON) is pleased to announce the opening of Georgia Oncology and Hematology Consultants.
  • Georgia Oncology and Hematology Consultants (GOHC) is providing care at its new clinic located at 1111 Glynco Parkway, Suite 35 in Brunswick.
  • American Oncology Network, LLC (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success of community oncology.
  • Georgia Oncology and Hematology Consultants (GOHC) is located on the southeast coast of Georgia, offering convenient access to quality cancer and hematology care for patients in Brunswick, Georgia.

Takeda to Present Rare Bleeding Disorders Research Highlighting Need for Real-World Evidence at NHF Bleeding Disorders Conference 2020

General Health, Pharmaceutical, Health, Blood, Body fluids, Anatomy, Transfusion medicine, Hematology, Coagulopathy, Bleeding
Saturday, August 1, 2020 - 4:00pm

Takeda Pharmaceutical Company Limited ( TSE: 4502/NYSE:TAK ) (Takeda), today presented three abstracts at the 72nd National Hemophilia Foundations Bleeding Disorders Conference, underscoring the need for real-world evidence (RWE) to advance patient-centric treatment in bleeding disorders.

Key Points: 
  • Takeda Pharmaceutical Company Limited ( TSE: 4502/NYSE:TAK ) (Takeda), today presented three abstracts at the 72nd National Hemophilia Foundations Bleeding Disorders Conference, underscoring the need for real-world evidence (RWE) to advance patient-centric treatment in bleeding disorders.
  • These data highlight the gaps in diagnosis and treatment still prevalent in the bleeding disorders community today, and spotlight opportunities for Takeda to better support these patients.
  • We have 70+ years of experience driving innovation for patients and a broad portfolio of 11 products across multiple bleeding disorders.
  • Our experience as leaders in hematology means we are well prepared to meet todays needs as we pursue future developments in the treatment of bleeding disorders.